Acadian Asset Management’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q3 | – | Sell |
-275,506
| Closed | -$2.4M | – | 1893 |
|
|
2018
Q2 | $2.4M | Buy |
275,506
+122,893
| +81% | +$1.11M | 0.01% | 519 |
|
|
2018
Q1 | $1.55M | Buy |
152,613
+85,344
| +127% | +$717K | 0.01% | 638 |
|
|
2017
Q4 | $327K | Buy |
67,269
+25,201
| +60% | +$123K | ﹤0.01% | 881 |
|
|
2017
Q3 | $191K | Buy |
42,068
+90
| +0.2% | +$423 | ﹤0.01% | 924 |
|
|
2017
Q2 | $211K | Buy |
41,978
+941
| +2% | +$4.21K | ﹤0.01% | 936 |
|
|
2017
Q1 | $196K | Buy |
41,037
+2,544
| +7% | +$12.9K | ﹤0.01% | 1048 |
|
|
2016
Q4 | $217K | Sell |
38,493
-4,937
| -11% | -$27.1K | ﹤0.01% | 991 |
|
|
2016
Q3 | $242K | Sell |
43,430
-26,380
| -38% | -$174K | ﹤0.01% | 936 |
|
|
2016
Q2 | $489K | Sell |
69,810
-61,048
| -47% | -$430K | ﹤0.01% | 781 |
|
|
2016
Q1 | $866K | Sell |
130,858
-24,889
| -16% | -$183K | ﹤0.01% | 647 |
|
|
2015
Q4 | $1.6M | Buy |
155,747
+65,218
| +72% | +$756K | 0.01% | 609 |
|
|
2015
Q3 | $1.07M | Buy |
90,529
+88,291
| +3,945% | +$976K | 0.01% | 669 |
|
|
2015
Q2 | $20K | Buy |
2,238
+53
| +2% | +$400 | ﹤0.01% | 1092 |
|
|
2015
Q1 | $14K | Buy |
+2,185
| New | +$13.5K | ﹤0.01% | 1157 |
|
Acadian Asset Management's JNP Position: Q3 2018 in Review
Acadian Asset Management sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q3 2018, closing a stake of 275,506 shares — an estimated $2.4M sold.
Acadian Asset Management first reported a position in JNP in Q1 2015 and held it in 14 quarters. The position peaked at $2.4M in Q2 2018. 0 funds tracked by Wall St. Rank hold JNP as of Q3 2018.
- Acadian Asset Management reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
- Acadian Asset Management sold 275,506 Juniper Pharmaceuticals, Inc. Common Stock shares in Q3 2018, an estimated $2.4M.
- Acadian Asset Management first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q1 2015 and held it in 14 quarters.
- Acadian Asset Management's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $2.4M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q3 2018.
Based on Acadian Asset Management's 13F filing for Q3 2018, filed 30 Oct 2018.